Objective: To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<5, 5-10 and 10+years) postvaccination. Design: A retrospective, matched case-control study PARTICIPANTS: Cases-all adult (age 18-79) TBE cases in Switzerland reported via the national mandatory disease reporting surveillance system from 2006 to 2020 (final n=1868). Controls-community controls from a database of randomly selected adults (age 18-79) participating in a 2018 cross-sectional study of TBE vaccination in Switzerland (final n=4625). Primary outcome measures: For cases and controls, the number of TBE vaccine doses received and the time since last vaccination were determined. Individuals were classified as being 'unvaccinated' (0...
Background: Tick-borne encephalitis (TBE) is endemic in southern and eastern districts of Germany. A...
AbstractTwo series of experiments (in vivo and in vitro) were performed to determine protective leve...
Since the 2008/9 influenza season, the I-MOVE multicentre case–control study measures influenza vacc...
Objective: To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<...
OBJECTIVE: To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<...
BACKGROUND: In 2006, the Swiss Federal Office of Public Health (FOPH) decided recommending a prolong...
BACKGROUND Tick-borne encephalitis (TBE) is increasing in Europe. We aimed to evaluate the immuno...
BACKGROUND: In 2006, the Swiss Federal Office of Public Health decided recommending a prolongation o...
Funding Information: This study was sponsored by Pfizer Inc. Publisher Copyright: © 2022 The Authors...
BACKGROUND Overall incidence and geographic range of Tick-borne Encephalitis (TBE), a vaccine pre...
Tick-borne encephalitis (TBE) vaccines are effective and well tolerated. However, their acceptance a...
AbstractBackgroundIntervals longer than recommended are frequently encountered between doses of tick...
The goal of this study was to evaluate timeliness of Tick-borne Encephalitis vaccination uptake amon...
Funding Information: Funding: This study was sponsored by Pfizer Inc. Publisher Copyright: © 2021 by...
This study is concerned with the statistical analysis of tick-borne encephalitis (TBE) antibody decr...
Background: Tick-borne encephalitis (TBE) is endemic in southern and eastern districts of Germany. A...
AbstractTwo series of experiments (in vivo and in vitro) were performed to determine protective leve...
Since the 2008/9 influenza season, the I-MOVE multicentre case–control study measures influenza vacc...
Objective: To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<...
OBJECTIVE: To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<...
BACKGROUND: In 2006, the Swiss Federal Office of Public Health (FOPH) decided recommending a prolong...
BACKGROUND Tick-borne encephalitis (TBE) is increasing in Europe. We aimed to evaluate the immuno...
BACKGROUND: In 2006, the Swiss Federal Office of Public Health decided recommending a prolongation o...
Funding Information: This study was sponsored by Pfizer Inc. Publisher Copyright: © 2022 The Authors...
BACKGROUND Overall incidence and geographic range of Tick-borne Encephalitis (TBE), a vaccine pre...
Tick-borne encephalitis (TBE) vaccines are effective and well tolerated. However, their acceptance a...
AbstractBackgroundIntervals longer than recommended are frequently encountered between doses of tick...
The goal of this study was to evaluate timeliness of Tick-borne Encephalitis vaccination uptake amon...
Funding Information: Funding: This study was sponsored by Pfizer Inc. Publisher Copyright: © 2021 by...
This study is concerned with the statistical analysis of tick-borne encephalitis (TBE) antibody decr...
Background: Tick-borne encephalitis (TBE) is endemic in southern and eastern districts of Germany. A...
AbstractTwo series of experiments (in vivo and in vitro) were performed to determine protective leve...
Since the 2008/9 influenza season, the I-MOVE multicentre case–control study measures influenza vacc...